New Insulins,Biosimilars,and Insulin Therapy

Kurtzhals P , Nishimura E , Haahr H , Høeg-Jensen T , et al. Commemorating insulin's centennial: Engineering insulin pharmacology towards physiology. Trends Pharmacol Sci 2021; 42: 620–639.

Kjeldsen TB , Hubalék F , Hjørringgaard CU , et al. Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans. J Med Chem 2021; 64: 8942–8950.

Hövelmann U , Brøndsted L , Kristensen NR , et al. Insulin icodec: An insulin analog suited for once-weekly dosing in type 2 diabetes. Diabetes, 2020; 69 (Suppl 1): 237-OR.

Godman B , Haque M , Leong T , et al. The current situation regarding long-acting insulin analogues including biosimilars among African, Asian, European, and South American countries; findings and implications for the future. Front Public Health, 2021; 9: 671961.

Godman B , Haque M , Kumar S , et al. Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future. Curr Med Res Opin 2021; 37: 1529–1545.

Knox R. Insulin insulated: Barriers to competition and affordability in the United States insulin market. J Law Biosci, 2020; 7(1): lsaa061.

Levy J , Chowdhury ZM , Socal MP , Trujillo AJ . Changes associated with the entry of a biosimilar in the insulin glargine market. JAMA Intern Med 2021 Jun 28; e212769. doi: 10.1001/jamainternmed.2021.2769. Online ahead of print.

FDA. FDA Works to Ensure Smooth Regulatory Transition of Insulin and Other Biological Products. https://www.fda.gov/news-events/press-announcements/fda-works-ensure-smooth-regulatory-transition-insulin-and-other-biological-products2020. Accessed July 31, 2021 .

FDA. Insulin Gains New Pathway to Increased Competition. https://www.fda.gov/news-events/press-announcements/insulin-gains-new-pathway-increased-competition2020. Accessed July 31, 2021 .

GaBI. FDA opens pathway to biosimilar insulin products. https://www.gabionline.net/guidelines/FDA-opens-pathway-to-biosimilar-insulin-products. Accessed July 17, 2021 .

Zhang RM , Puri R , McGill JB . Update on biosimilar insulins: A US perspective. BioDrugs 2020; 34: 505–512.

Moyers JS , Hansen RJ , Day JW , et al. Preclinical characterization of once weekly basal insulin Fc (BIF). J Endocrine Soc 2021; 5 (Suppl 1): p A442.

Heise T , Chien J , Beals J , et al. Basal insulin Fc (BIF), a novel insulin suited for once weekly dosing for the treatment of patients with diabetes mellitus. J Endocrine Soc 2021; 5 (Suppl 1): p A329.

Frias JP , Chien J , Zhang Q , et al. Once weekly basal insulin Fc (BIF) is safe and efficacious in patients with type 2 diabetes mellitus (T2DM) previously treated with basal insulin. J Endocrine Soc 2021; 5 (Suppl 1): p A448.

Heise T , Nørskov M , Nosek L , Kaplan K , Famulla S , Haahr HL . Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/ml in type 1 diabetes. Diabetes Obes Metab, 2017; 19: 1032–1039.

Bailey TS , Pettus J , Roussel R , et al. Morning administration of 0.4U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes. Diabetes Metab, 2018; 44: 15–21.

Rosenstock J , Cheng A , Ritzel R , et al. More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naïve type 2 diabetes: The randomized head-to-head BRIGHT trial. Diabetes Care, 2018; 41: 2147–2154.

Philis-Tsimikas A , Klonoff DC , Khunti K , et al. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: The randomised, head-to-head CONCLUDE trial. Diabetologia, 2020; 63: 698–710.

Svensson A-M , Ekelund J , Miftaraj M , Eliasson B . Efficacy and safety of treatment with new basal insulin analogues in type 1 diabetes: Nation-wide survey. Diabetes Ther, 2020; 11: 725–734.

Riddell MC , Gallen IW , Smart CE , et al. Exercise management in type 1 diabetes: A consensus statement. Lancet Diabetes Endocrinol, 2017; 5: 377–390.

EMA. Summary of the European public assessment report for Abasaglar. https://www.ema.europa.eu/en/medicines/human/EPAR/abasaglar-previously-abasria. Accessed July 16, 2021 .

FDA. Basaglar (insulin glargine injection). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205692orig1s000toc.cfm. Accessed July 16, 2021 .

EMA. Summary of the European public assessment report for Semglee. https://www.ema.europa.eu/en/medicines/human/EPAR/semglee. Accessed July 16, 2021 .

FDA. Drug Approval Package: SEMGLEE. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210605Orig1s000TOC.cfm. Accessed July 16, 2021 .

EMA. Summary of the European public assessment report for Admelog. https://www.ema.europa.eu/en/medicines/human/EPAR/insulin-lispro-sanofi. Accessed July 19, 2021 .

FDA. Drug Approval Package: Admelog (insulin lispro). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209196Orig1s000TOC.cfm. Accessed July 19, 2021 .

EMA. Summary of the European public assessment report for SAR-Asp. https://www.ema.europa.eu/en/medicines/human/EPAR/insulin-aspart-sanofi. Accessed July 19, 2021 .

EMA. Summary of the European public assessment report for Kixelle. https://www.ema.europa.eu/en/medicines/human/EPAR/kixelle. Accessed July 22, 2021 .

Walmart. Walmart Revolutionizes Insulin Access & Affordability for Patients with Diabetes with the Launch of the First and Only Private Brand Analog Insulin. https://corporate.walmart.com/newsroom/2021/06/29/walmart-revolutionizes-insulin-access-affordability-for-patients-with-diabetes-with-the-launch-of-the-first-and-only-private-brand-analog-insulin2021. Accessed July 31, 2021 .

Carter AW , Heinemann L . If PBMs guard access to drugs, then quis custodiet ipsos custodies? (who will guard the guardians?). J Diabetes Sci Technol, 2016; 10: 1406–1410.

Sun B , Sengupta N , Rao A , et al. Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: The phase 3 INSTRIDE 1 and INSTRIDE 2 studies. BMC Endocr Disord, 2021; 21: 129.

Karonova TL , Mayorov AY , Magruk MA , et al. Safety and efficacy of GP40071 compared with originator insulin aspart (NovoRapid^® Penfill^®) in type 1 diabetes mellitus. J Comp Eff Res, 2021; 10: 763–775.

Tarigan TJE , Dwijayanti A , Setyowati S , Louisa M . Immunogenicity and efficacy of insulin glargine biosimilar ezelin versus originator insulin glargine in patients with type 2 diabetes. Diabetes Metab Syndr Obes, 2021; 14: 107–116.

Feng W , Chen W , Jiang S , Du L , Zhu D . Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial. Diabetes Obes Metab. 2021; 23: 1786–1794.

Yan X , Jiang S , Lou Y , Zhou Z. Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus^®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial. Diabetes Obes Metab 2021 Jun 13. doi: 10.1111/dom.14463. Online ahead of print.

Taki K , Koyanagi M , Nagaoka S , Shingaki T . Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: A post-marketing safety study. Curr Med Res Opin, 2020; 36: 1975–1983.

Mayorov AY , Mosikian AA , Alpenidze DN , et al. Efficacy and safety of GP40021 insulin lispro biphasic compared with Humalog Mix 25 in type 2 diabetes mellitus patients. J Comp Eff Res, 2021; 10: 55–66.

Hussein Z , Aziz NA , Dhanaraj E , Brahmachari B , Kothekar M . Safety and effectiveness of a biosimilar biphasic insulin in the management of diabetes mellitus during routine clinical practice in Asian patients. Med J Malaysia, 2020; 75: 372–378.

HEC Pharma. http://www.hecpharm.com/en/productapi.aspx?ProductsCateID=62&parid=53?ProductsCateID=53&parid=39. Accessed July 31, 2021 .

Goyal P , Pai HV , Kodali P , et al. Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine. PLoS One, 2021; 16: e0253168.

Avgerinos I , Papanastasiou G , Karagiannis T , Michailidis T , Liakos A , Mainou M , Matthews DR , Tsapas A , Bekiari E . ^,Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 2021 Jun 9. doi: 10.1111/dom.14461.

Billion L , Charleer S , Verbraeken L , et al. Glucose control using fast-acting insulin aspart in a real-world setting: A 1-year, two-centre study in people with type 1 diabetes using continuous glucose monitoring. Diabetes Obes Metab 2021 Aug 16. doi: 10.1111/dom.14527. Online ahead of print.

Danne T , Schweitzer MA , Keuthage W , et al. Impact of fast-acting insuin aspart on glycemic control in patients with type 1 diabetes using intermittent scanning continuous glucose monitoring within a real-world setting: The GoBolus Study. Diabetes Technol Ther, 2021; 23: 203–212.

Faggionato E , Schiavon M , Dalla Man C . Modeling between subject variability in subcutaneous absorption of a fast-acting insulin analogue by a nonlinear mixed effects approach. Metabolites, 2021; 11: 235.

Grosman B , Wu D , Parikh N , et al. Fast-acting insulin aspart (Fiasp^®) improves glycemic outcomes when used with MiniMed TM 670G hybrid closed-loop system in simulated trials compared to NovoLog^® . Comput Methods Programs Biomed, 2021; 205: 106087.

Colmegna P , Cengiz E , Garcia-Tirado J , Kraemer K , Breton MD . Impact of accelerating insulin on an artificial pancreas system without meal announcement: An in silico examination. J Diabetes Sci Technol, 2021; 15: 833–841.

Bode B , Garg S , Norwood P , et al. Compatibility and safety of ultra rapid lispro with continuous subcutaneous insulin infusion in patients with type 1 diabetes: PRONTO-Pump Study. Diabetes Technol Ther, 2021; 23: 41–50.

Warren M , Bode B , Cho JI , et al. Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2. Diabetes Obes Metab, 2021; 23: 1552–1561.

Hsu L , Buckingham B , Basina M , et al. Fast-acting insulin aspart use with the MiniMed^TM 670G system. Diabetes Technol Ther, 2021; 23: 1–7.

Ozer K , Cooper AM , Ahn LP , Waggonner CR , Blevins TC . Fast acting insulin aspart compared with insulin aspart in the Medtronic 670G Hybrid Closed Loop System in type 1 Diabetes: An open label crossover study. Diabetes Technol Ther, 2021; 23: 286–292.

Bode BW , Carlson A , Liu R , et al. Ultra rapid lispro demonstrates similar time in target range to lispro with a hybrid closed-loop system. Diabetes Technol Ther 2021 Jul 16. doi: 10.1089/dia.2021.0184. Online ahead of print.

Lee MH , Paldus B , Vogrin S , et al. Fast-acting insulin aspart versus insulin aspart using a second-generation hybrid closed-loop system in adults with type 1 diabetes: A randomized, open-label, crossover trial. Diabetes Care 2021 Aug 6; dc210814. doi: 10.2337/dc21-0814. Online ahead of print.

Russell SJ , Balliro C , Ekelund M , et al. Improvements in glycemic control achieved by altering the t max setting in the iLet^® bionic pancreas when using fast-acting insulin aspart: A randomized trial. Diabetes Ther, 2021; 12: 2019–2033.

Svehlikova E , Mursic I , Augustin T , et al. Pharmacokinetics and pharmacodynamics of three different formulations of insulin aspart: A randomized, double-blind, crossover study in men with type 1 diabetes. Diabetes Care, 2021; 44: 448–455.

Andersen G , Meiffren G , Famulla S , et al. ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes Obes Metab, 2021; 23: 961–970.

Majdpour D , Tsoukas MA , Yale JF , et al. Fully automated artificial pancreas for adults with type 1 diabetes using multiple hormones: Exploratory experiments. Can J Diabetes 2021 Feb 20:S1499–2671(21)00045-9. doi: 10.1016/j.jcjd.2021.02.002. Online ahead of print.

Jarosinski MA , Dhayalan B , Rege N , Chatterjee D , Weiss MA . “Smart” insulin-delivery technologies and intrinsic glucose-responsive insulin analogues. Diabetologia, 2021; 64:1016–1029.